Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products

项目摘要和相关性 项目总结： 这个合作项目的广泛的长期目标是发现小分子 可以取代抗体作为PD-1检查点抑制剂的治疗。到目前为止，还不是很小 分子已被批准用于这一应用，尽管小分子的好处 药物治疗中对生物制品的过度使用是显而易见的。这个项目利用了一个大型的 收集(多达30,000个样本)具有独特结构的海洋微生物代谢物 被证明是开发抗癌药物的可靠来源。此收藏，可用 在加州大学斯克里普斯海洋研究所，威廉·费尼奇博士将与 与南京中医药大学尹璐博士的癌症生物学实验室合作， 用商品化的PD-1细胞生物测定法筛选选择性抑制剂 有约束力的。当活性代谢物被发现时，它们将在各种次生代谢物中进行筛选 化验显示有选择性结合。最后，将生产经过验证的PD-1结合抑制剂 通过大规模种植获得数毫克量，并提供给卢博士进行评估 选择肿瘤的小鼠和大鼠异种移植模型。 相关性： 该项目旨在通过发现小分子来提高癌症的免疫治疗水平。 选择性地与蛋白质PD-1结合，当与PDL-1结合时，负责 免疫系统失活。用新的抗体(蛋白质)疗法取代目前的抗体(蛋白质)疗法 小分子药物有可能提高治疗效果，并将明显降低药品成本。

Project Summary and Relevance Project Summary: The broad, long-term objective of this collaborative project is the discovery of small molecule therapeutics that can replace antibodies as inhibitors of the PD-1 checkpoint. To date, no small molecules have been approved for this application, although the benefits of small molecules over biologicals in drug therapy is clear. This project capitalizes on the existence of a large collection (up to 30,000 samples) of structurally unique marine microbial metabolites that have shown to be a solid source for the development of anticancer agents. This collection, available at the Scripps Institution of Oceanography, UCSD, from Dr. William Fenical will be interfaced with the cancer biology lab of Dr. Yin Lu at the Nanjing University of Chinese Medicine, to screen for selective inhibitors using a commercially-available cell-based bioassay for PD-1 binding. When active metabolites are discovered, they will be screened in a variety of secondary assays to show selective binding. Finally, verified PD-1binding inhibitors will be produced in multi-milligram amounts by large-scale cultivation and provided to Dr. Lu for evaluation in mouse and rat xenograph models of select cancers. Relevance: This project aims to improve on the immunotherapy of cancer by discovering small molecules that selectively bind to the protein PD-1, which when bound to PDL-1 is responsible for the deactivation of the immune system. Replacing the current antibody (protein) therapy with a small molecule drug is likely to improve treatment efficacy and will clearly reduce drug cost.